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Summary By using a quantitative RNA-RNA solution hybridisation method, the average number of mdrl
RNA transcripts per cell was measured in total nucleic acid extracts of leukaemic cells from patients with
acute leukaemia. The results in different types of leukaemia were (number of patients with detectable mdrl
RNA/total number of patients; median number of transcripts per cell in samples with detectable mdrl RNA);
de novo untreated acute myelocytic leukaemia (AML): 20/44; 0.7, secondary acute myelocytic leukaemia: 8/13;
1.1, acute lymphocytic (ALL) and undifferentiated leukaemia: 5/14; 0.6, relapsed leukaemia: 7/15; 0.7.
Forty-six patients with de novo untreated acute leukaemia (AML: n = 34, ALL: n = 12) were evaluable for
response to induction chemotherapy. Twelve of 18 patients (67%) with detectable mdrl RNA levels achieved
complete remission compared to 23 of 28 (82%) with undetectable levels (P = 0.40). The remission duration
tended to be longer among patients with undetectable mdrl RNA (P = 0.08). Leukaemic cells were analysed
on consecutive occasions in 12 patients. The level of expression increased in four and decreased in two. In
conclusion, expression of mdrl RNA is common in acute untreated leukaemia. However, treatment with
cytostatic drugs seems only rarely to increase the proportion of leukaemic cells that express mdrl RNA.
Expression of the mdrl gene could be one of several equally important factors contributing to drug resistance
in acute leukaemia.
Multiple drug resistance (MDR) can be induced in cell lines
by several chemically unrelated drugs, such as anthracyclines,
vinca alkaloids, and podophyllotoxins. Resistant cells
accumulate less drug (Dan0, 1973), due to an energy depen-
dent drug efflux mediated by a 170 kD glycoprotein (P-
glycoprotein) (Juliano & Ling, 1976; Kartner et al., 1985).
Concomitant incubation with agents that prevent drug efflux,
e.g. verapamil, cyclosporin A, and quinidine can restore
intracellular drug concentration and overcome resistance in
vitro (Tsuruo et al., 1983; Twentyman et al., 1990). Cell lines
expressing the MDR phenotype may also have decreased
sensibility to drugs that do not induce MDR like mitoxan-
trone and amsacrine (Taylor et al., 1991).
cDNA clones encoding the gene for P-glycoprotein (mdrl)
have been isolated (Gros et al., 1986; Van der Bliek et al.,
1988), and transfection studies have confirmed that expres-
sion of the mdrl gene is sufficient to create the MDR
phenotype (Ueda et al., 1987a). The mdrl gene is frequently
expressed in certain tissues such as liver, large and small
intestine, kidney, adrenal cortex and pancreas (Fojo et al.,
1987; Thiebaut et al., 1987).
Analyses of human tumours have shown that malignant
cells from organs that normally express mdrl RNA often
express mdrl. Untreated neoplasms that occasionally express
mdrl include acute leukaemia in adults, non-Hodgkin's lym-
phoma and neuroblastoma (Goldstein et al., 1989). An
association between mdrl RNA expression in leukaemic cells
and response to chemotherapy in acute myelocytic leukaemia
(AML) has earlier been suggested (Sato et al., 1990; Pirker et
al., 1991; Marie et al., 1991). In sarcoma of childhood and
neuroblastoma, expression of P-glycoprotein determined with
the monoclonal antibody C219 was found to be an important
prognostic factor (Chan et al., 1991; 1990). Another group
using the same monoclonal antibody found that P-glyco-
protein expression was restricted to normal cells in neuro-
blastoma biopsies (Favrot et al., 1991). In P-glycoprotein
positive resistant multiple myeloma verapamil has been
shown to increase the effect of vincristine, doxorubicin and
prednisone chemotherapy in some but not all patients
(Salmon et al., 1991).
To further delineate the clinical relevance of mdrl expres-
sion in leukaemic cells, we have quantified the mdrl RNA
expression in 92 samples of peripheral blood leukaemic cells
from 76 patients with untreated de novo or secondary acute
leukaemia and relapsed acute leukaemia. Leukocytes from
seven blood donors, cell line K562 and two vincristine resis-
tant sublines, three human liver specimens and the hepatoma
cell line HepG2 were also investigated.
Material and methods
Patients
Ninety-two samples of leukaemic cells from 76 patients were
analysed. The study included 58 patients with de novo un-
treated acute leukaemia-44 with AML, 12 with acute lym-
pocytic leukaemia (ALL), two with acute undifferentiated
leukaemia (AUL), 15 patients with relapsed leukaemia (sam-
ples from ten had also been analysed at first presentation)
and 13 with secondary AML (12 patients with AML evolving
from a myelodysplastic syndrome and one patient who had
previously received cytostatic treatment). Median ages of the
different patient subgroups were: de novo AML 64 years
(15-87), ALL and AUL 36 years (17-80), secondary AML
69 years (46-86). The median white blood cell count was 38
(4-544) x 1091-1. In patients studied > 70% of the mono-
nuclear cells in peripheral blood were leukaemic cells.
Mononuclear cells were isolated from peripheral blood by
centrifugation on Lymphoprep® (Nycomed A/S, Oslo, Nor-
way), frozen to - 90°C in a programmed freezer in RPMI
1640 medium (Gibco, Life Technologies Ltd, Paisley, Scot-
land) supplemented with 1% L-glutamine, 50% human
serum and 10% dimethylsulfoxide, and stored in liquid nitro-
gen.
The patients were treated between 1982 and 1991 and
received combination chemotherapy according to different
protocols. The majority of the patients with AML, in which
an attempt to achieve complete remission (CR) was made,
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received daunorubicin-vincristine-ara-C, mitoxantrone-etopo-
side-ara-C, or daunorubicin-ara-C-thioguanine (Table I).
Patients with ALL received daunorubicin-cyclophosphamide-
vincristine-prednisone-L-asparaginase. CR was defined as
normal cellularity and less than 5% blasts in the bone mar-
row in combination with normal peripheral blood values.
Patients who did not enter remission following at least two
induction courses were defined as having resistant disease.
Patients who died during induction treatment or received
palliative low dose cytostatic treatment were not considered
evaluable for response to chemotherapy.
The study was approved by the local ethics committee.
Normal leukocytes, liver specimens and cell lines
Mononuclear cells from seven healthy blood donors were
separated from buffy coats by centrifugation on Lympho-
prep®. Monocytes were separated from lymphocytes by
adhesion to a plastic culture flask. Granulocytes were
isolated from the buffy coats after removal of mononuclear
cells. The remaining pellets (approximately 15 ml, containing
red blood cells, platelets and granulocytes) were mixed with
10 ml of human plasma, 4 ml of 4.5% dextran (T250, Phar-
macia, Uppsala, Sweden) containing 1000 IU of heparin, and
allowed to sediment for 1.5 h at 4°C. The supernatant con-
taining the granulocytes was collected. The isolated cells were
frozen as pellets, containing approximately 60 x 106 cells, in
liquid nitrogen and kept at - 90°C.
The cell line HepG2 and three specimens of human normal
liver, obtained during surgery (liver resection because of
metastatic cancer) were also analysed. The specimens were
immediately after removal frozen in liquid nitrogen and then
kept at - 90°C.
As controls, cell line K562 and the vincristine resistant
sublines K562/Vcr3O and K562/Vcrl50 were analysed. The
resistant cell lines were developed by growing K562 cells in
medium with increasing concentrations of vincristine. K562/
Vcr3O and K562/Vcrl50 were maintained in medium with
vincristine concentrations 30 and 150 nM, respectively, and
expressed MDR characteristics (not shown).
RNA analysis
Nucleic acids extracts were prepared from approximately
60 x 106 cells or in case of liver specimens approximately
100mg of tissue (Durnam & Palmiter, 1983). The samples
were lysed in 4ml of 1 x SET (1% SDS, 20 mM Tris-HCI,
pH 7.5, and 10 mM EDTA), homogenised in a Polytron®
(Kinematica, Kriens, Switzerland), and then treated with pro-
teinase K 200iLg ml-l (Merck, Darmstadt, Germany) for
45 min at 45°C. After extraction with phenol/chloroform and
precipitation with ethanol the precipitate was dissolved in
Table I Patients with AML, evaluable for response to chemotherapy. Clinical characteristics and
expression of mdrl RNA in leukaemic cells
Pat Sex/Age
No. years
I M/73
2 M/85
3 F/48
4 M/38
5 F/37
6 M/40
7 M/72
8 F/68
9 M/56
10 F/41
11 M/73
12 F/57
13 F/50
14 F/38
15 F/15
16 M/71
17 M/46
18 F/64
19 M/49
20 F/53
21 F/53
22 M/42
23 F/78
24 M/72
25 M/77
26 F/59
27 F/76
28 M/74
29 M/63
30 F/64
31 F/63
32 M/34
33 M/54
34 M/65
FAB type
Ml
Ml
Ml
Ml
M2
M2
M2
M3
M4
Ml
Ml
M2
M2
M4
M4
M4
M4
M5
M5
M5
M5
M5
M5
M5
Ml
M4
M5
M5
M5
M2
M2
M4
M4
M5
mdrl RNA
transcripts/
cell
0.8
1.3
0.3
1.2
0.2
0.7
0.2
0.3
0.8
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
0.2
0.3
1.6
0.6
0.8
<0.15
<0.15
<0.15
<0.15
<0.15
No of
courses
to CR
I
1
2
4
3
2
2
2
2
4
2
3
2
3
2
2 14 4
1
resistant
resistant
resistant
resistant
resistant
resistant
resistant resistant
resistant
resistant
Chemotherapy
Mxn, VplI6, AraC
Mxn, Vpl6, AraC
Mxn, Vpl6, AraC
Mxn, Vpl6, AraC,
Ams
Dau, Vcr, AraC
Dox, Vcr, AraC, Thg
Mxn, Vpl6, AraC
Dau, Vcr, AraC
Dau, Vcr, AraC
Mxn, Vpl6, AraC
Dau, Vcr, AraC
Ida, AraC, Mxn,
Vpl6, Ams
DOx, Vcr, AraC, Thg,
Ams
Dau, Vcr, AraC
Dau, Vcr, Vpl6
Dau, AraC, Thg
Dau, Vcr, AraC
Dau, Vcr, AraC
Dau, Vcr, AraC
Dau, Vcr, AraC
Mxn, Vpl6, AraC
Mxn, Vpl6, AraC
Dau, AraC, Thg
Acla, Thg, AraC
Dau, Vcr, AraC
Dau, Vcr, AraC
Dau, Thg, AraC,
Vpl6, Ams
Dau, Vcr, AraC
Dau, AraC, Thg,
Mxn, Vpl6
Mxn, Vpl6, AraC, Ams
Dau, Vcr, AraC, Ams
Dau, AraC, Vcr,
Vpl6, Ams
Dau, Vcr, AraC,
Ams, Vpl6
Dau, Vcr, Ams
Duration of
CR days
308
52
172
104
287
215
405
165
65+
2255 +
213
262
155
614
192
893
321
39
1095
Ofthe five patients where no remission duration is stated, one refused further treatment, three died
from other causes than leukaemia and one underwent an allogeneic bone marrow transplantation. For
explanation of abbreviations of cytostatic drugs, see Table V.268 A. GRUBER et al.
0.2 x SET and aliquots were taken for determination of DNA
concentration by Hoechst fluorometry (Labarca & Paigen,
1980). Plasmid pGEM4 (Promega Corporation, Madison,
WI, USA) carrying the 1383 basepair mdrl cDNA sequence
5A, was kindly provided by M.M. Gottesman and I. Pastan,
NCI, USA (Ueda et al., 1987b). A 403 nucleotides long
antisense probe (with 393 nucleotides transcribed from mdrl
cDNA, position 2561-2168) was generated by in vitro trans-
cription of Stul (New England Biolabs, Inc, Beverly, USA)
cleaved 5A with SP6 RNA polymerase (Promega Corpora-
tion) in the presence of 35S-UTP (>37 x 106 MBq mmol-',
Amersham, England). Non incorporated nucleotides were
separated from the transcript on a Sephadex G-50 column
(Nickcolumn, Pharmacia). Polyacrylamide gel electrophoresis
showed that >90% of the transcripts were of the expected
size. Two types of sense complementary to the labelled
antisense were used. One 1732 nucleotides long unlabelled
sense RNA was transcribed by T7 RNA polymerase (Pro-
mega Corporation) from 5A after linearisation with NaeI
(New England Biolabs, Inc). A shorter sense, 439 nucleotides
long, was transcribed by SP6 RNA polymerase from EcoR I
(New England Biolabs, Inc) cleaved plasmid pGem-3Zf( + )
(Promega Corporation), into which the 393 basepair
sequence, which constitutes the labelled antisense probe had
been subcloned. After Sephadex G-50 chromatography, the
RNA containing fraction was ethanol precipitated, dissolved
in 0.2 x SET and the RNA concentration determined
spectrophotometrically at 260 nm.
Hybridisations were performed essentially as described
previously (Durnam & Palmiter, 1983; Nygren et al., 1991).
Aliquots of the nucleic acid extracts, or unlabelled sense
RNA, were adjusted to 20p1l with 0.2 x SET and mixed with
30 x 103 counts per min (c.p.m.) ofantisense probe, dissolved
in 20fIl hybridisation solution (0.6 M NaCl, 4 mM EDTA,
20 mM Tris-HCI, pH 7.5, 7.5 mM DTT, and 25% deionised
recrystallised formamide), and incubated for 18 h at 68°C.
Subsequently, the samples were treated with 1 ml of
40 tLg ml- RNase A (Sigma Chemical Company, St Louis,
MO, U.S.A.), 2fg ml' RNase TI (Sigma), 100jig ml-'
salmon sperm DNA (Sigma), 0.3 M NaCl, 2 mM EDTA, and
10 mM Tris-HCI, (pH 7.5) and incubated for 45 min at 37°C.
After addition of 100 glI trichloroacetic acid, the samples were
kept on ice for 30 min, and the RNase resistant precipitates
were collected on Whatman GF/C filters (Whatman Interna-
tional Ltd, Maidstone, England). After addition of 4 ml scin-
tillation liquid (Insta-gel; Packard Instrument Company,
Downers Grove, IL, USA), the radioactivity was determined
in a liquid scintillation counter (Packard). The background
radioactivity, measured in RNase treated samples containing
the same amount of probe but no sense RNA or extract, was
below 0.5% of the input value. Samples classified as positive
for mdrl RNA showed at least twice the background
radioactivity and a proportional increase in radioactivity with
increasing amounts of added extract (Figures la and b). The
quantities of mdrl RNA in the extracts were determined by
comparison with a standard curve, generated by hybridisa-
tions with increasing amounts of sense RNA (Steen et al.,
1990) (Figure lc). The average number of mdrl RNA trans-
cripts per cell could be calculated based on the standard
curve, the molecular weight of sense RNA, c.p.m. per jig of
DNA in the positive extracts, Avogadros number (6 x 1023
molecules in a mole) and the assumption of a DNA content
of 6 pg/cell. The limit of detection in extracts containing
30 iLg of DNA was 7.5 x I05 transcripts of mdrl RNA,
corresponding to 0.15 RNA copies per cell. Cell extract
corresponding to at least 30gig of DNA was analysed in all
samples classified as having undetectable levels of mdrl
RNA.
Recovery ofRNA and DNA
The recovery of RNA was measured by the addition of
135 x 103 c.p.m. of labelled RNA transcribed with SP6 RNA
polymerase from plasmid pGEM 5Zf (+) (Promega Cor-
poration) to cell samples lysed in 1 x SET. Thereafter the
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Figure 1 Hybridisation between 35S-labelled RNA probe and
total nucleic acid extract from (a) two samples from patients
expressing 0.7 and 1.3 transcripts per cell respectively ( 0-) and
two samples where no mdrl RNA could be detected (-0). (b)
K562/Vcr3O 0 - K562/Vcrl50 - - which express 100 and 200
mdrl RNA transcripts per cell respectively. (c) shows a standard
curve used for calculation of mdrl RNA transcripts (hybridisa-
tion between probe and in vitro transcribed sense).
samples were treated with proteinase K, extracted with
phenol/chloroform, precipitated with ethanol dissolved in
0.2 x SET, treated with trichloroacetic acid, the remaining
radioactivity collected on a GF/C filter and counted in a
liquid scintillation counter. The recovery of DNA was cal-
culated by comparison of DNA concentration in cell samples
before and after the extraction and precipitation procedure.
The recovery of RNA was between 70-80% and of DNA
80-90%, respectively.
n I vMDRI GENE EXPRESSION IN ACUTE LEUKAEMIA 269
Specificity and reproducibility ofthe method
The specificity of the method was tested by performing an
RNase protection assay with 50 pg of 439 nucleotides long
sense, RNA extracts from K562, its vincristine resistant sub-
line K562/Vcrl50, HepG2 and leukaemic cells from two
patients with AML (one with 3.9 mdrl RNA transcripts per
cell and one with undetectable levels of mdrl RNA). RNA
was extracted from approximately 20 x 106 cells (Andersson
et al., 1992) and hybridised with 50 x 103 c.p.m. of labelled
sense under conditions identical to those described above.
The intactness of the extracted RNA was confirmed by
agarose gel electrophoresis. After RNase treatment, extrac-
tion with phenol/chloroform and ethanol precipitation, RNA
was size separated by electrophoresis through a denaturating
5% polyacrylamide gel. Subsequently the gel was dried and
the hybridised probe detected by autoradiography for 12 h.
An RNA ladder was used as marker of length in nucleotides.
The assay revealed one major protected fragment of the
expected size in the lanes of K562/Vcrl50, HepG2, the
leukaemic cells with detectable mdrl RNA and sense RNA.
No probe could be seen in the lanes of K562 and the
leukaemic cells with undetectable mdrl RNA (Figure 2).
The human mdr2 gene (also called mdr3), which is ex-
pressed in liver and in some B cell lymphatic leukaemias but
not in myelocytic leukaemias (Herweijer et al., 1990), shows a
high DNA sequence homology with the mdrl gene (Chin et
al., 1989). However, in the region encompassed by the
labelled antisense probe, the homology is only 69% and the
longest homologous sequence consists of 14 nucleotides,
preventing cross-hybridisation under the used stringent con-
ditions. This is also shown by the single protected fragment
in the RNase protection assay of HepG2 cells, which exp-
resses both the mdrl and the mdr3 gene (Van der Bliek et al.,
1987).
To check the reproducibility of the method 19 samples
with detectable mdrl RNA and nine samples with undetec-
table levels were extracted and hybridised on a second
occasion. All samples with undetectable levels at first analysis
also had undetectable mdrl RNA levels at the second
analysis. The coefficient ofvariation ofcalculated mdrl RNA
transcripts per cell among the 19 samples with detectable
mdrl RNA levels was 25% (Figure 3).
The coefficient of variation using the two different sense
RNAs for quantification was 4%.
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Figure 2 RNase protection assay was performed as described in
Material and methods. Amounts of RNA loaded; HepG2: 90 lAg,
mdrl RNA probe: 15 x 103c.p.m., K562: 36jkg, K562/Vcrl5O:
40 lAg, patient A (with undetectable mdrl RNA): 34lAg, patient B
(with 3.9 mdrl RNA transcripts per cell): 67 g, sense RNA:
50pg. Numbers indicate fragment length in nucleotides.
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Figure 3 Reproducibility of the method. Nineteen cell samples
with detectable mdrl RNA levels, extracted, hybridised and
quantified on a second occasion. Coefficient of variation 25%.
Statistical analyses
The relationship between mdrl expression and age was ana-
lysed using the Mann Whitney U test. 2 x 2 tables were
analysed with Fisher's exact test. Remission duration was
analysed using the method of Kaplan and Meier and com-
parisons made by the log rank test (Peto et al., 1977).
Results
Leukocytesfrom blood donors
The expression of mdrl RNA in lymphocytes, monocytes,
and granulocytes from seven blood donors is shown in Table
II. All seven lymphocyte samples had detectable mdrl RNA
levels with a median value of 0.4 (0.2-1.0) mdrl RNA
transcripts per cell. Four of the monocyte samples had detec-
table levels, while mdrl RNA could not be detected in the
granulocytes from any individual.
Cell lines and liver specimens
In the maternal cell line K562 no mdrl RNA could be
detected. The two vincristine resistant sublines K562/Vcr3O
and K562/Vcrl50 contained approximately 100 and 200
mdrl RNA transcripts per cell, respectively, (Figure lb).
HepG2 contained 6.4, and the three samples from human
liver 9.6, 6.7 and 5.5 mdrl RNA transcripts per cell, respec-
tively.
)0 Leukaemic cells
10 Mdrl RNA expression in the different subtypes of acute
leukaemia is shown in Table III. Leukaemic cells from 20
(45%) of 44 patients with untreated de novo AML had
detectable levels of mdrl RNA with a median expression of
0.7 (0.2-2.2) transcripts per cell. In secondary AML,
leukaemic cells from 8 of 13 patients had detectable mdrl
RNA with a median level of 1.1 (0.6-3.9) transcripts per cell.
The expression in samples with detectable levels was
significantly higher in cells from patients with secondary
leukaemia than in cells from patients with de novo AML
(P<0.05). Cells from five of seven patients with relapsed
AML and cells from two of eight samples from patients with
relapsed ALL/AUL had detectable mdrl RNA. The level of
mdrl expression in cells with detectable mdrl RNA from
patients with relapsed leukaemia was not higher than in cells
with detectable levels from untreated patients. Thirty-four
patients with AML and 12 patients with ALL were evaluable270 A. GRUBER et al.
Table II MdrI RNA transcripts per cell in leukocytes from healthy
blood donors
Donor
no. Lymphocytes Monocytes Granulocytes
I 1.0 0.4 <0.15
2 0.2 <0.15 <0.15
3 0.2 <0.15 <0.15
4 0.4 <0.15 <0.15
5 0.4 1.2 <0.15
6 0.3 0.4 <0.15
7 0.5 0.4 <0.15
The purity of the cell fractions were: lymphocytes >90%,
monocytes > 70% and of granulocytes > 80% as determined by
counting of the cells in a Coulter multisizer.
Table III Expression of mdrl RNA according to leukaemia subtype
and disease status
Patients with detectable
Number of mdrl RNA - median number
Type ofleukaemia patients oftranscripts per cell (range)
AML 44 20-0.7 (0.2-2.2)
AML 7 5-0.9 (0.5-2.2.)
relapse
AML 13 8-1.1 (0.6-3.9)
secondary
ALL and AUL 14 5-0.6 (0.2-1.1)
ALL and AUL 8 2-0.6 (0.4-0.8)
relapse
for response to induction treatment. The relationship
between mdrl RNA expression and achievement of CR is
shown in Table IV. If patients with AML and ALL are
analysed together 23 of 28 patients with leukaemic cells
without detectable mdrl RNA entered CR compared to 12
of 18 with leukaemic cells where mdrl RNA could be
detected (P= 0.40). Most patients had a short remission
duration (less than one year). The remission duration tended
to be longer among patients whose leukaemic cells had
undetectable levels of mdrl RNA but the difference was not
significant, (P = 0.08) when patients with AML and ALL are
analysed together, P = 0.15 when only patients with AML
are included) (Figure 4).
Among the 24 patients with AML who achieved a CR
there was no difference in the number of chemotherapy
courses needed to achieve CR between patients with detec-
table mdrl RNA levels and patients with undetectable levels.
The 20 patients, with de novo AML, with detectable mdrl
RNA levels in their leukaemic cells had a median age of 74
years (37-87) as compared to 54 years (15-78) for the
24 AML patients without detactable mdrl RNA levels
(P<0.02). Considering all 76 patients (two patients who
changed their expression are analysed twice) the median age
of the 36 patients with detectable mdrl RNA levels was 66
years (17-87) compared to 54 years (15-81) for the 42
patients with undetectable levels (P<0.02). The median age
of the 24 AML patients who achieved CR was 53 years, as
Table IV Remission rate in relation to mdrl RNA expression
Diagnosis
mdrl RNA No. of No. ofpatients
expression patients achieving CR (0)
AML 34 24 (70%)
>0.15 tc 14 9 (64%)
<0.15 tc 20 15 (75%)
ALL 12 11
>0.lStc 4 3
<0.15 tc 8 8
tc denotes transcripts per cell.
100
0
E 50
E o B u A
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Duration of complete remission (years)
Figure 4 Duration of first remission in AML patients with
detectable (A); n = 7 and with undetectable (B); n = 12 levels of
mdrl RNA (P= 0.15).
compared to 64 years for the 10 patients with resistant
disease (P = 0.48).
No association was observed in AML patients between
FAB subtype (Bennett et al., 1976) or peripheral white blood
cell count and expression of the mdrl gene.
Two or more consecutive samples were analysed in 12
patients, ten at diagnosis and relapse, one during a resistant
relapse and one primary resistant patient (Table V). One of
six patients (pt 6) who initially had undetectable levels of
mdrl RNA increased the expression to 0.7 transcripts per cell
after multiple chemotherapy. In three of six patients (pts 2, 7,
8) who initially had detectable mdrl RNA in their cells there
was a small increase, and in two (pts 1 and 4) there was a
decrease of mdrl RNA expression.
Discussion
An accurate method for mdrl RNA quantification is impor-
tant to clarify the relationship between mdrl expression in
leukaemic cells and response to chemotherapy and also to
evaluate the effect of chemotherapy on mdrl expression. We
have employed a solution hybridisation technique, which
allows reproducible quantification of less than one transcript
of mdrl RNA per cell in a few million cells. Like other
investigators we found that expression of the mdrl gene is
quite common in untreated acute leukaemia (Sato et al.,
1990; Noonan et al., 1990; Pirker et al., 1991; Marie et al.,
1991). However, the level of expression is low, generally
below one transcript per cell compared to 6-9 transcripts per
cell in human liver. The level ofexpression in leukaemic cells
and liver is in the same order of magnitude as that observed
by Noonan et al. (1990) who used polymerase chain reaction
to quantify mdrl RNA.
The interpretation of the clinical significance of mean levels
of mdrl RNA is complicated by the difficulty in distin-
guishing between situations where many cells express low
levels, or a small clone of leukaemic cells express high levels.
These alternative situations may differently infl4ence the
antileukaemic effect of chemotherapy. The impact of mdrl
RNA levels on response to chemotherapy also depends on
the association between mdrl RNA levels and amount of
P-glycoprotein on the cell surface which needs to be clarified.
The biologicial significance of the low mdrl RNA expres-
sion as well as the demonstrated variation in mdrl RNA
concentrations in the different leukocyte fractions from heal-
thy individuals needs to be further investigated. Studies of
drug efflux have indicated that the mdrl gene expression may
vary in subpopulations of lymphocytes (Bines et al., 1991).
We found that a low mdrl RNA expression is common in
tumour cells from patients with acute leukaemia but could
not find any association between mdrl expression and
liability to achieve a CR. The majority of patients withMDRI GENE EXPRESSION IN ACUTE LEUKAEMIA 271
Table V Consecutive analyses of mdrl RNA expression in leukaemic cells from 12 patients
Pat Age Diag- Status of MdrJ RNA
no. Sex years nosis disease transcripts/cell Chemotherapy
I F 58 AML diagnosis 0.3
relapse <0.15 Dau, Vcr, AraC
2 M 85 AML diagnosis 1.3
relapse 2.2 Mxn, Vpl6, AraC
3 F 48 AML diagnosis 0.3
relapse 0.4 Mxn, Vpl6, AraC
resistant 0.3 Ida, AraC
resistant 0.5 Ams, AraC, Vpl6, Carb
4 F 56 AML relapse 1.0 Mxn, Vpl6, AraC, Ams
resistant 0.4 Vcr, Dox, AraC, Vpl6
5 F 64 AML diagnosis <0.15
resistant <0.15 Mxn, Vpl6, AraC
6 F 56 AML diagnosis <0.15
resistant relapse 0.7 Mxn, Vp16, AraC, Ams,
Carb, Thg
7 F 17 ALL diagnosis 0.2
relapse 0.4 Dau, Vcr, Cy, Asp,
Vpl6, Mxn, AraC
8 F 33 ALL diagnosis 0.5
relapse 0.8 Cy, Dox, Vcr, Mxn,
Vpl6, AraC
resistant 0.9 Ams, AraC, Carb, Vpl6
9 F 63 ALL diagnosis <0.15
relapse <0.15 Cy, Dau, Vcr, Asp, Vpl6,
AraC, Ams
resistant <0.15 Mxn, Vpl6, AraC
10 M 45 ALL diagnosis <0.15
relapse <0.15 Cy, Dau, Vcr, Asp, Vpl6,
AraC, Ams
11 M 21 ALL diagnosis <0.15
relapse <0.15 Cy, Dau, Vcr, Asp, Vpl6
AraC, Thg, Mcp, Mtx
12 F 30 ALL diagnosis <0.15
resistant relapse <0.15 Dau, Vcr, AraC, Cy, VpI6
Dau = daunorubicin, Vcr = vincristine, AraC = cytarabine,
Vpl6 = etoposide, Ida = idarubicin, Ams = amsacrine,
Cy = cyclophosphamide, Asp = asparaginase, Dox = doxorubicin,
Thg = thioguanine, Mcp = mercaptopurine, Mtx = methotrexate.
detectable and with undetectable levels of mdrl RNA had a
remission duration of less than one year. However, all
patients with a remission duration of more than 18 months
had undetectable mdrl RNA in their leukaemic cells at
diagnosis. Most likely expression of the mdrl gene influences
response to chemotherapy in combination with several other
mechanisms of resistance, for example non P-glycoprotein
mediated multiple drug resistance, altered topoisomerase II
activity or increased levels of glutathion-transferases (Danks
et al., 1987; Harker et al., 1989; Beck, 1989; Holmes et al.,
1990; Schuurhuis et al., 1991). The fact that our patients with
AML received different combinations ofcytostatic drugs may
also hamper the interpretation of the assocation between
mdrl expression and response to chemotherapy. Furthermore
comparison of remission frequency may also be too blunt a
tool to differentiate between resistant and chemosensitive
disease.
The findings in 12 patients analysed on consecutive
occasions and in patients with relapsed leukaemia support
the notion that treatment with cytostatic drugs seldom seems
to select clones of leukaemic cells that express mdrl RNA.
In the present series mdrl expression was more common in
elderly patients, which might be one explanation for the more
dismal prognosis in the elderly with AML. In secondary
AML that generally is chemotherapy resistant the median
level of expression among the samples with detectable mdrl
RNA was higher than in de novo AML and the two patients
with the highest expression were found in this group.
A negative association between mdrl RNA expression and
remission frequency and/or duration of first CR has been
reported in other studies where more uniform treatment pro-
tocols have been used (Sato et al., 1990; Pirker et al., 1991;
Marie et al., 1991). In the study by Sato et al., only in one of
Mxn = mitoxantrone,
Carb = carboplatin,
Acla = aclarubicin,
seven patients analysed on consecutive occasions there was
an increase of mdrl expression and in the study by Marie et
al., two of four cases analysed on consecutive occasions
increased their mdrl expression, one was unchanged and one
changed from positive to negative. A negative relationship
between response to chemotherapy (CR or partial remission)
and P-glycoprotein expression, detected with the antibody
C219, in leukaemic cells from patients with AML and ALL
has also been demonstrated (Kuwarzuru et al., 1990). How-
ever, in another study where mdrl expression was determined
with the monoclonal antibody MRK16 P-glycoprotein was
not detected in any sample from 12 AML patients who were
investigated at diagnosis and at relapse (Ito et al., 1989). In
contrast, in another study where the antibody C219 was used
61-100% of the leukaemic cells from six of eight AML
patients studied at relapse were positive (Musto et al., 1991).
If mdrl expression is a main cause for resistance to
chemotherapy one would expect improvement of treatment
results by the use of resistance modifiers. Until now there is
only one AML patient reported in whom a resistance
modifier has been used to overcome drug resistance. In the
reported case no mdrl RNA could be detected in the
leukaemic cells at diagnosis. In contrast, the cells at relapse 4
months after CR were positive. The patient was retreated
with the original induction chemotherapy with the addition
ofcyclosporin A and attained a second CR of short duration
(Sonneveld et al., 1990). From the results ofthe present study
and those by other investigators we conclude that expression
of the mdrl gene could be one of several mechanisms of
primary resistance to chemotherapy in acute leukaemia. But
that selection of leukaemic cells that express mdrl RNA is a
rare event following conventional antileukaemic treatment.272 A. GRUBER et al.
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